Qi Huang

Qi is a seasoned virologist with over 20 years of industry experience in major infectious diseases, including DNA and RNA viruses such as SARS-CoV-2 and hepatitis C. Qi has led all stages of drug research and development (R&D) including preclinical research and clinical development.

Prior to joining Atea, Qi held multiple senior-level leadership roles and most recently served as Chief Scientific Officer of Virology and Senior Vice President of R&D at Huahui Health, a biotechnology company focused on novel therapies for liver diseases. Prior to Huahui Health, Qi served as Vice President, Virology Discovery and Chief Scientific Officer, China Operations at Assembly Biosciences and held senior scientist positions at Presidio Pharmaceuticals and Rigel Pharmaceuticals. Qi began her career at the R.W. Johnson Pharmaceutical Research Institute of Johnson and Johnson.

Qi holds a B.Sc., in Genetics and Genetic Engineering from Fudan University, and a Ph.D., in Pharmacology and Molecular Sciences from Johns Hopkins University School of Medicine.